Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Latest Information Update: 08 Aug 2022
At a glance
- Drugs RSV 276 (Primary) ; RSV/deltaNS2/delta1313/I1314L (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- 23 Jun 2022 Pooled results from NCT03227029 and NCT0342223, published in the Journal of Infectious Diseases.
- 09 Dec 2021 New trial record